Cargando…
Impact on follow‐up strategies in patients with primary sclerosing cholangitis
BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies in PSC with the hypothesis that regular imaging improves survival. METHODS: We...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084018/ https://www.ncbi.nlm.nih.gov/pubmed/35535655 http://dx.doi.org/10.1111/liv.15286 |
_version_ | 1785021646966358016 |
---|---|
author | Bergquist, Annika Weismüller, Tobias J. Levy, Cynthia Rupp, Christian Joshi, Deepak Nayagam, Jeremy Shanika Montano‐Loza, Aldo J. Lytvyak, Ellina Wunsch, Ewa Milkiewicz, Piotr Zenouzi, Roman Schramm, Christoph Cazzagon, Nora Floreani, Annarosa Liby, Ingalill Friis Wiestler, Miriam Wedemeyer, Heiner Zhou, Taotao Strassburg, Christian P. Rigopoulou, Eirini Dalekos, George Narasimman, Manasa Verhelst, Xavier Degroote, Helena Vesterhus, Mette Kremer, Andreas E. Bündgens, Bennet Rorsman, Fredrik Nilsson, Emma Jørgensen, Kristin Kaasen von Seth, Erik Cornillet Jeannin, Martin Nyhlin, Nils Martin, Harry Kechagias, Stergios Wiencke, Kristine Werner, Mårten Beretta‐Piccoli, Benedetta Terziroli Marzioni, Marco Isoniemi, Helena Arola, Johanna Wefer, Agnes Söderling, Jonas Färkkilä, Martti Lenzen, Henrike |
author_facet | Bergquist, Annika Weismüller, Tobias J. Levy, Cynthia Rupp, Christian Joshi, Deepak Nayagam, Jeremy Shanika Montano‐Loza, Aldo J. Lytvyak, Ellina Wunsch, Ewa Milkiewicz, Piotr Zenouzi, Roman Schramm, Christoph Cazzagon, Nora Floreani, Annarosa Liby, Ingalill Friis Wiestler, Miriam Wedemeyer, Heiner Zhou, Taotao Strassburg, Christian P. Rigopoulou, Eirini Dalekos, George Narasimman, Manasa Verhelst, Xavier Degroote, Helena Vesterhus, Mette Kremer, Andreas E. Bündgens, Bennet Rorsman, Fredrik Nilsson, Emma Jørgensen, Kristin Kaasen von Seth, Erik Cornillet Jeannin, Martin Nyhlin, Nils Martin, Harry Kechagias, Stergios Wiencke, Kristine Werner, Mårten Beretta‐Piccoli, Benedetta Terziroli Marzioni, Marco Isoniemi, Helena Arola, Johanna Wefer, Agnes Söderling, Jonas Färkkilä, Martti Lenzen, Henrike |
author_sort | Bergquist, Annika |
collection | PubMed |
description | BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies in PSC with the hypothesis that regular imaging improves survival. METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow‐up from 1 January 2000, until death or last clinical follow‐up alive. The primary endpoint was all‐cause mortality. RESULTS: A broad variety of different follow‐up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow‐up, was 0.61 (0.47–0.80) for scheduled imaging with and without ERCP; 0.64 (0.48–0.86) for US/MRI and 0.53 (0.37–0.75) for follow‐up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high‐grade dysplasia as a time‐dependent covariate, HR 0.57 (0.44–0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow‐up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed. CONCLUSIONS: Follow‐up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures. |
format | Online Article Text |
id | pubmed-10084018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100840182023-04-11 Impact on follow‐up strategies in patients with primary sclerosing cholangitis Bergquist, Annika Weismüller, Tobias J. Levy, Cynthia Rupp, Christian Joshi, Deepak Nayagam, Jeremy Shanika Montano‐Loza, Aldo J. Lytvyak, Ellina Wunsch, Ewa Milkiewicz, Piotr Zenouzi, Roman Schramm, Christoph Cazzagon, Nora Floreani, Annarosa Liby, Ingalill Friis Wiestler, Miriam Wedemeyer, Heiner Zhou, Taotao Strassburg, Christian P. Rigopoulou, Eirini Dalekos, George Narasimman, Manasa Verhelst, Xavier Degroote, Helena Vesterhus, Mette Kremer, Andreas E. Bündgens, Bennet Rorsman, Fredrik Nilsson, Emma Jørgensen, Kristin Kaasen von Seth, Erik Cornillet Jeannin, Martin Nyhlin, Nils Martin, Harry Kechagias, Stergios Wiencke, Kristine Werner, Mårten Beretta‐Piccoli, Benedetta Terziroli Marzioni, Marco Isoniemi, Helena Arola, Johanna Wefer, Agnes Söderling, Jonas Färkkilä, Martti Lenzen, Henrike Liver Int Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases BACKGROUND & AIMS: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies in PSC with the hypothesis that regular imaging improves survival. METHODS: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow‐up from 1 January 2000, until death or last clinical follow‐up alive. The primary endpoint was all‐cause mortality. RESULTS: A broad variety of different follow‐up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow‐up, was 0.61 (0.47–0.80) for scheduled imaging with and without ERCP; 0.64 (0.48–0.86) for US/MRI and 0.53 (0.37–0.75) for follow‐up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high‐grade dysplasia as a time‐dependent covariate, HR 0.57 (0.44–0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow‐up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed. CONCLUSIONS: Follow‐up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures. John Wiley and Sons Inc. 2022-05-16 2023-01 /pmc/articles/PMC10084018/ /pubmed/35535655 http://dx.doi.org/10.1111/liv.15286 Text en © 2022 The Authors. Liver International published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases Bergquist, Annika Weismüller, Tobias J. Levy, Cynthia Rupp, Christian Joshi, Deepak Nayagam, Jeremy Shanika Montano‐Loza, Aldo J. Lytvyak, Ellina Wunsch, Ewa Milkiewicz, Piotr Zenouzi, Roman Schramm, Christoph Cazzagon, Nora Floreani, Annarosa Liby, Ingalill Friis Wiestler, Miriam Wedemeyer, Heiner Zhou, Taotao Strassburg, Christian P. Rigopoulou, Eirini Dalekos, George Narasimman, Manasa Verhelst, Xavier Degroote, Helena Vesterhus, Mette Kremer, Andreas E. Bündgens, Bennet Rorsman, Fredrik Nilsson, Emma Jørgensen, Kristin Kaasen von Seth, Erik Cornillet Jeannin, Martin Nyhlin, Nils Martin, Harry Kechagias, Stergios Wiencke, Kristine Werner, Mårten Beretta‐Piccoli, Benedetta Terziroli Marzioni, Marco Isoniemi, Helena Arola, Johanna Wefer, Agnes Söderling, Jonas Färkkilä, Martti Lenzen, Henrike Impact on follow‐up strategies in patients with primary sclerosing cholangitis |
title | Impact on follow‐up strategies in patients with primary sclerosing cholangitis |
title_full | Impact on follow‐up strategies in patients with primary sclerosing cholangitis |
title_fullStr | Impact on follow‐up strategies in patients with primary sclerosing cholangitis |
title_full_unstemmed | Impact on follow‐up strategies in patients with primary sclerosing cholangitis |
title_short | Impact on follow‐up strategies in patients with primary sclerosing cholangitis |
title_sort | impact on follow‐up strategies in patients with primary sclerosing cholangitis |
topic | Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084018/ https://www.ncbi.nlm.nih.gov/pubmed/35535655 http://dx.doi.org/10.1111/liv.15286 |
work_keys_str_mv | AT bergquistannika impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT weismullertobiasj impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT levycynthia impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT ruppchristian impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT joshideepak impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT nayagamjeremyshanika impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT montanolozaaldoj impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT lytvyakellina impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT wunschewa impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT milkiewiczpiotr impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT zenouziroman impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT schrammchristoph impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT cazzagonnora impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT floreaniannarosa impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT libyingalillfriis impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT wiestlermiriam impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT wedemeyerheiner impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT zhoutaotao impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT strassburgchristianp impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT rigopouloueirini impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT dalekosgeorge impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT narasimmanmanasa impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT verhelstxavier impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT degrootehelena impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT vesterhusmette impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT kremerandrease impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT bundgensbennet impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT rorsmanfredrik impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT nilssonemma impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT jørgensenkristinkaasen impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT vonsetherik impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT cornilletjeanninmartin impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT nyhlinnils impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT martinharry impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT kechagiasstergios impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT wienckekristine impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT wernermarten impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT berettapiccolibenedettaterziroli impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT marzionimarco impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT isoniemihelena impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT arolajohanna impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT weferagnes impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT soderlingjonas impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT farkkilamartti impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT lenzenhenrike impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis AT impactonfollowupstrategiesinpatientswithprimarysclerosingcholangitis |